CUL4B promotes prostate cancer progression by forming positive feedback loop with SOX4

a, b The expression of CUL4B in PCa tissues compared with normal prostate samples in {"type":"entrez-geo","attrs":{"text":"GSE6956","term_id":"6956"}}GSE6956 (a) and {"type":"entrez-geo","attrs":{"text":"GSE68545","term_id":"68545"}}GSE68545 (b) dataset. c The expression of CUL4B in primary and metastatic PCa tissues compared with the matched normal prostate samples in {"type":"entrez-geo","attrs":{"text":"GSE35988","term_id":"35988"}}GSE35988 dataset. d–g Analysis of CUL4B expression in TCGA dataset. d CUL4B levels in PCa subgroups with different TNM stages; e CUL4B levels in PCa subgroups with different Gleason scores; f the correlation between CUL4B expression and biochemical recurrence-free survival (P？=？0.015, Log-rank test) and g clinical recurrence survival (P？=？0.01, Log-rank test) in the TCGA cohort. h Kaplan–Meier survival analysis of microarray data from 94 PCa cases stratified by high and low CUL4B expression levels (P？=？0.02, Log-rank test). i–k Analysis of CUL4B expression in Qilu cohort by IHC assay. i Representative IHC images of CUL4B expression of benign prostate tissue and PCa tissue with different Gleason score in Qilu cohort. j Kaplan–Meier survival analysis of PCa cases from Qilu cohort according to high and low CUL4B expression levels (P？=？0.17, Log-rank test). k Kaplan–Meier survival analysis of PCa cases with Pre PSA level 4–10？ng/ml in Qilu cohort stratified by CUL4B levels (P？=？0.01, Log-rank test). *P？<？0.05, **P？<？0.01, ***P？<？0.001. PCa prostate cancer, TCGA The Cancer Genome Atlas, IHC immunohistochemistr